United Therapeutics (NASDAQ:UTHR) CEO Sells $5,573,270.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $586.66, for a total transaction of $5,573,270.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $23,767,356.58. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $574.29 on Thursday. The firm’s 50-day moving average is $532.71 and its 200-day moving average is $492.68. The stock has a market cap of $25.17 billion, a price-to-earnings ratio of 20.58, a PEG ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.19 EPS. Sell-side analysts predict that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Torren Management LLC bought a new position in shares of United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter worth approximately $31,000. Wilmington Savings Fund Society FSB increased its holdings in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. bought a new position in shares of United Therapeutics during the fourth quarter worth approximately $48,000. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of research analyst reports. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Oppenheimer upped their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Wells Fargo & Company upped their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a report on Tuesday, March 31st. Finally, Bank of America increased their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $601.50.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Company to present encouraging clinical and program data (ARTISAN/PHINDER interim analyses) at ISHLT — results highlight earlier detection/management of pulmonary hypertension, right?ventricular benefits with high?dose treprostinil, and progress on lung donor expansion/xenotransplantation, which support longer?term pipeline value and revenue upside. Read More.
• Positive Sentiment: Analysts remain constructive with multiple price?target raises and a consensus “Moderate Buy” (~$601.50 average), which provides valuation support that can limit downside if upcoming clinical/earnings news is positive.
• Positive Sentiment: Longer?term bull thesis highlighted around manufactured organs/xenotransplantation — bullish pieces argue these programs (if successful and approved) could materially re?rate the company over the next several years. Read More.
• Neutral Sentiment: United Therapeutics will report Q1 results before market open on May 6; Zacks notes the company has setup attributes that could support an earnings beat — this calendar catalyst can drive short?term volatility in either direction. Read More. Read More.
• Neutral Sentiment: Some institutional reweighting — Asset Management One modestly trimmed its stake (?5.1%), a small adjustment rather than a large outflow that’s unlikely to move the stock materially on its own. Read More.
• Neutral Sentiment: Unusually large options activity has been reported, indicating elevated short?term trading and hedging interest — this can amplify intraday moves but is directionally ambiguous. Read More.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.5M) in mid?April, reducing her stake by ~19% — a high?profile insider sale that often raises investor concerns about near?term sentiment. Read More.
• Negative Sentiment: CFO James Edgemond sold 10,000 shares (~$5.78M) around the same dates — multiple senior executive sales in quick succession increase perceived selling pressure. Read More.
• Negative Sentiment: Additional director insider sales have been reported, adding to the pattern of recent insider liquidations that can weigh on near?term investor sentiment. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.